Full-Time
Updated on 9/4/2026
Biotech firm discovering cancer therapies.
$222.3k - $243.3k/yr
Watertown, MA, USA
In Person
Travel to domestic and international CDMO sites is expected approximately 20% of the time.
Master's, PhD
See people who can refer or advise you
Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.
Company Size
51-200
Company Stage
Series A
Total Funding
$1.1B
Headquarters
Stamford, Connecticut
Founded
2021
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget
Conference Attendance Budget
Stock Options
Company Equity
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Wellness Program
Gym Membership
Treeline and Roche collaborate on TLN-121 combo trial for BCL. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline's BCL6 degrader, TLN-121, with Roche's CD20xCD3 T-cell-engaging bispecific antibodies, glofitamab (Columvi) and mosunetuzumab (Lunsumio), in patients with B-cell lymphomas (BCL). The trial will assess the combinations in separate cohorts, including individuals with diffuse large B-cell lymphoma (DLBCL). Under the collaboration, Treeline Biosciences will sponsor and oversee the Phase I dose-escalation and expansion study, with Roche supplying glofitamab and mosunetuzumab for particular expansion cohorts. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline co-founder and CEO Josh Bilenker said: "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. Clinical Trials Arena is excited to build on that progress in collaboration with Roche. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumour activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T-cells and B-cells." TLN-121 has shown single-agent activity, including complete responses, in an ongoing Phase I trial in late-line DLBCL, follicular lymphoma and T follicular helper peripheral T-cell lymphoma. Treeline is a clinical-stage biopharmaceutical company with a pipeline in oncology, neurology and immunology. Last month, Evexta Bio and Roche entered a clinical trial collaboration and supply agreement for a Phase Ib study investigating the combination of rupitasertib and giredestrant in patients with advanced or metastatic breast cancer. This marks the first clinical collaboration for Evexta Bio involving its investigational compound rupitasertib and for Roche with giredestrant, its selective estrogen receptor degrader (SERD). Give your business an edge with its leading industry insights.
Roche cooperates with Treeline on lymphoma therapy. Roche is collaborating with the US biotech company Treeline Biosciences on the development of a new combination therapy for certain forms of lymphoma. 02.09.2026 04:50 In the collaboration, Treeline's drug candidate TLN-121 in combination with Roche's drugs Columvi (glofitamab) and Lunsumio (mosunetuzumab) will be investigated. The combinations are to be studied in patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), as Treeline announced on Wednesday. Treeline will finance and conduct the phase 1 study, while Roche will provide the already approved cancer drugs glofitamab and mosunetuzumab for certain study groups. Financial details were not disclosed. Treeline plans to begin the combined treatment in the fourth quarter of 2026. Preclinical investigations have provided evidence that TLN-121 could enhance the effect of the two Roche therapies. TLN-121 is currently already being tested as a monotherapy in a phase 1 study.
Treeline, Roche partner on TLN-121 lymphoma trial. Phase 1 study will evaluate TLN-121 with Roche's glofitamab and mosunetuzumab in patients with B-cell lymphomas. September 2, 2026 Associate Editor, Contract Pharma Treeline Biosciences Inc. has entered into a clinical trial collaboration and supply agreement with Roche to study TLN-121, Treeline's BCL6 degrader, alongside Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in patients with B-cell lymphomas. The Phase 1 study will evaluate the combinations in separate cohorts, including patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of B-cell lymphoma. Treeline will sponsor and conduct the Phase 1 dose-escalation and expansion study, while Roche will provide glofitamab and mosunetuzumab for specified expansion cohorts. Treeline expects to begin combination dosing in those cohorts in the fourth quarter of 2026. "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche," said Josh Bilenker, M.D., co-founder and CEO of Treeline. TLN-121 is already being evaluated as a single agent in an ongoing Phase 1 clinical trial, where Treeline said it has shown activity, including complete responses in late-line DLBCL, follicular lymphoma (FL), and T follicular helper peripheral T-cell lymphoma (TFH PTCL). The collaboration is intended to test whether degrading BCL6 can make lymphoma cells more responsive to T-cell-engaging therapies, a strategy supported by Treeline's preclinical findings. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumor activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T- and B-cells," Bilenker added.
BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN), Standard BioTools Inc. (Nasdaq - LAB). * Jun 19, 2026 BALA CYNWYD, Pa., June 19, 2026 (GLOBE NEWSWIRE) - Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. AstroNova, Inc. (Nasdaq - ALOT) Under the terms of the Merger Agreement, AstroNova will be acquired by Arcline Investment Management for $29.00 per share in cash in an all-cash transaction with a total enterprise value of approximately $272 million. The investigation concerns whether the AstroNova Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Open Lending Corporation (Nasdaq - LPRO) Under the terms of the Merger Agreement, Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share. The investigation concerns whether the Open Lending Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Huntsman Corporation (NYSE - HUN) Under the terms of the Merger Agreement, Huntsman will be acquired by Olin Corporation (NYSE - OLN) whereby Huntsman shareholders will receive 0.5476 shares in Olin for every one (1) share of Huntsman. Upon completion of the transaction, Olin shareholders will own approximately 54.5% and Huntsman shareholders will own approximately 45.5% of the combined company. The investigation concerns whether the Huntsman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Standard BioTools Inc. (Nasdaq - LAB) Under the terms of the Merger Agreement, Standard BioTools will be acquired by Treeline Biosciences, Inc. At the closing of the proposed combination, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company. The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Treeline to go public via reverse merger with Standard BioTools. News reporter. Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.